116026-94-9Relevant articles and documents
An efficient synthesis of 2-amino-5-chloro-3-pyridinecarbox-aldehyde and 5-amino-2-chloro-4-pyridinecarboxaldehyde
Hou, Chuan-Jin,Guo, Wei-Lei,Liu, Xiao-Ning,Yang, Da-Wei
, p. 21 - 23 (2011)
Efficient synthetic routes to the title compounds 2-amino-5-chloro-3- pyridinecarboxaldehyde (1a) and 5-amino-2-chloro-4-pyridinecarboxaldehyde (1b) are reported. Both compounds are important substrates in the synthesis of naph-thyridine derivatives. Copyright by Walter de Gruyter Berlin Boston.
New Straightforward Quinoline Synthesis from the Mannich Reaction of α-Ketohydrazones
Bailliez, Vincent,El Kaim, Laurent,Michaut, Valerie
, p. 109 - 118 (2007/10/03)
The addition of α-ketohydrazones to 2-acetamidobenzaldehyde proceeds efficiently in the presence of N-benzylpiperazine to afford in good to high yields the expected Mannich adducts; these are easily converted to quinoline derivatives under acidic conditio
Inhibitors of Cyclic AMP Phosphodiesterase. 3. Synthesis and Biological Evaluation of Pyrido and Imidazolyl Analogues of 1,2,3,5-Tetrahydro-2-oxoimidazoquinazoline
Venuti, Michael C.,Stephenson, Robert A.,Alvarez, Robert,Bruno, John J.,Strosberg, Arthur M.
, p. 2136 - 2145 (2007/10/02)
Hybridization of structural elements of 1,2,3,5-tetrahydro-2-oxoimidazoquinazoline ring system common to the cyclic AMP (cAMP) phosphodiesterase (PDE) inhibitors lixazinone (RS-82856,1) and anagrelide (3) with complementary features of other PDE inhibitor cardiotonic agents prompted the design and synthesis of the title compounds 7a-d, 11, 12, and 13a,b.The necessary features of these compounds were determined within the framework of the proposed active-site models for the high affinity form of cAMP PDE inhibited by cGMP (type IV).Evaluation of these targets, both in vitro as inhibitors of platelet or cardiac type IV PDE or in vivo as inotropic agents in the pentobarbital-anesthetized dog model of congestive heart failure, showed that these structure possessed negligibly enhanced activities over the parent heterocyclic system, and remained significantly inferior to 1 in all respects.This difference is ascribed to the absence of the N-cyclohexyl-N-methylbutyramidyl-4-oxy side chain of 1.The proposal that the acidic lactam-type functionality, common to the type IV PDE inhibitor inotropic agents such as 4-6 and 8-10, mimics the polarizable cyclic phosphate moiety of cAMP suggested that the side chain of 1 may function as an effective surrogate for selected characteristics of the adenine portion of cAMP.However, the results of this study show that incorporation of adenine-like hydrogen-bonding functionalities common to other type IV PDE inhibitors into the 1,2,3,5-tetrahydro-2-oxoimidazoquinazoline system did not enhance activity to the levels observed for 1 analogues.These observations, coupled with the kinetic pattern of inhibition of type IV PDE observed for 1 and analogues, suggest that access to a secondary, lipophilic-tolerant binding site, possibly coincident with the adenine binding domain, and adjacent to the catalytic ribose-phosphate binding site of platelet and cardiac type IV PDE, is responsible for the increased potency of these compounds.
